Patheon Manufacturing Services was approved by the US Food and Drug Administration (FDA) as the second contract manufacturer of Auryxia (ferric citrate), a drug used during dialysis, for Keryx Biopharmaceuticals, a Boston-based biopharmaceutical company.

With the FDA approval, Patheon has rebuilt supply and will make Auryxia available to wholesalers. Auryxia was approved by the FDA in September 2014 and is indicated in the US for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

Source: Keryx Biopharmaceuticals